New Zealand

Home / Species & Products / Dogs / Vanguard Plus 5

Expand All
  • Approved uses/Indications

    Vanguard Plus 5 is approved to stimulate systemic immunity (both humoral and cell mediated) to the antigens contained in the vaccine.

    For the re-vaccination of healthy adult dogs as an aid in protection against canine distemper caused by canine distemper virus (CDV), infectious canine hepatitis caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza virus (CPI) and canine parvo viral enteritis caused by canine parvovirus (CPV). Contains attenuated strains of CD virus, CAV-2, CPI virus and CPV propagated on an established canine cell line. The CPV fraction is high titre (>170.0 TCID50/dose) and was attenuated by low passage (35 passages) on an established canine cell line that gives it the immunogenic properties capable of overriding maternal antibody interference earlier than conventional low titre vaccines.

    Vanguard Plus 5 is only available for use under the authority or prescription of a veterinarian.  

    Do not use in puppies 14 weeks of age or younger.  

  • Key Features

    Vanguard Plus 5 has been shown to provide at least 3 years duration of immunity against canine parvovirus, canine distemper and canine adenovirus-1 and canine adenovirus-21.

    Vanguard Plus 5 is a modified live vaccine (MLV). Advantages of MLV vaccines include2:

    • Rapid protection
    • Prolonged duration of immunity
    • Induction of a broader range of protection – IgA, IgG and Cell Mediated Immunity

  • Packaging

    Vanguard Plus 5 contains attenuated strains of canine distemper (CD) virus, canine adenovirus type II (CAV-2), canine parainfluenza (CPI) virus and canine parvovirus (CPV) propagated on an established canine cell line.

    Packed in lyophilised form in packs of 25 x 1 dose vials of vaccine with diluent.

  • Dosage & Administration

    Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well and administer 1mL subcutaneously or intramuscularly.

    For the re-vaccination of healthy adult dogs for canine parvovirus, canine distemper virus, canine parainfluenza and canine adenovirus 1 and 2. Do not use in puppies 14 weeks of age or younger.  

    Revaccination with a single dose at intervals of up to 3 years is recommended. For canine parainfluenza virus, revaccination with a single dose annually is recommended.

    The Vanguard Plus 5 label allows veterinarians the flexibility to choose revaccination intervals that best suit the individual animal’s needs and circumstances.

  • Precautions

    Do not use in puppies 14 weeks of age or younger.  .

    As with any vaccine, anaphylaxis may occur following use. In this event, an initial antidote of adrenaline is recommended and should be followed by appropriate supportive therapy.

    Prescription Animal Remedy. Keep out of reach of children. For animal treatment only.

  • Mandatories

    Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. VANGUARD is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No.A7448. RVM; Available only under Veterinary Authorisation.

    References:

    1. Mouzin DE et al. Duration of serologic response to five viral antigens in dogs, JAVMA 2004; p55-60
    2. Greene CE. Infectious Diseases of the Dog and Cat. WB Saunders, USA. 1998; p721-24
  • Contact Information

    For technical enquiries please phone Zoetis Technical Services on 0800 650 277.